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The glycocalyx, a gel-like layer covering the luminal surface of vascular endothelial cells has 27 
several key functions in maintaining homeostasis in the vasculature. Interest in the glycocalyx 28 
has significantly increased in the last decades and damage to this vital layer appears to influence 29 
progression and recovery in many disease processes. Pathological injury to the glycocalyx 30 
occurs in ischaemia–reperfusion, inflammation, sepsis, shock, burns and excessive shear stress. 31 
There is increasing evidence that iatrogenic interventions such as fluid therapy influence the 32 
integrity of the glycocalyx and can even worsen the initial injury from pathological events. 33 
Rapid infusion of crystalloids and colloids, hypervolaemia, hypernatraemia and 34 
hyperglycaemia have all been associated with increased glycocalyx shedding. Current 35 
treatment recommendations aim to minimise iatrogenic damage. In the future, interventions 36 















The glycocalyx is a gel-like layer covering the luminal surface of vascular endothelial cells. It 50 
is comprised of membrane-attached proteoglycans, glycosaminoglycan chains, glycoproteins 51 
synthesised by the endothelial cells and adherent plasma proteins. The glycocalyx is essential 52 
for maintaining homeostasis in the vasculature[1]. In the healthy state, the glycocalyx regulates 53 
vascular permeability, provides anti-coagulant and anti-adhesive effects on the surface of 54 
endothelial cells and can shield endothelial cells from oxidative stress[1; 2]. Additionally, the 55 
glycocalyx senses fluid shear forces and transmits these forces to endothelial cells, initiating 56 
nitric oxide-mediated vasorelaxation. Considering these key functions, interest in the 57 
glycocalyx has significantly increased in the last decades and damage to this vital layer appears 58 
to influence progression and recovery in many disease processes. To the author’s knowledge, 59 
the only reports on glycocalyx in horses relate to the reproductive tract[3-5], mesenchymal 60 
stem cells[6] and equine pulmonary intravascular macrophages[7]. Until species-specific 61 
information is available, findings form other species therefore have to be extrapolated to equine 62 
patients. Unfortunately, research in any species is hampered by the fragile nature of the layer 63 
and the fact that structure, thickness and composition vary between vascular beds and methods 64 
used to investigate the layer’s characteristics[2]. The glycocalyx is thinner where it covers the 65 
microcirculation (as little as 0.2 µm) and thicker in larger vessels (up to 8 µm)[8]. In addition, 66 
glycocalyx grown on epithelial cells in vitro is not equivalent to its in vivo counterpart[9]. 67 
Research is further complicated by the fact that the effects of damage not only depend on the 68 
glycocalyx but also the nature of the underlying epithelium, making findings from one vascular 69 
bed not necessarily transferable to other areas of the body. A popular method to evaluate 70 
glycocalyx damage that is widely used in clinical studies is measuring circulating glycocalyx 71 
components, often syndecan-1 and hyaluronan, in plasma or urine of patients. While the degree 72 
of glycocalyx shedding correlates well with disease severity, the reliability of circulating 73 
glycocalyx components as endothelial damage biomarkers has not been widely accepted. There 74 
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is insufficient direct evidence showing that circulating concentrations of glycocalyx 75 
components correlate with endothelial injury[2]. Many proposed concepts about glycocalyx 76 
function in health and disease are therefore still speculative and controversial and not always 77 
backed up by clinical evidence[2; 10; 11]. 78 
 79 
Vascular permeability and transvascular fluid flux 80 
In the healthy state, the glycocalyx serves as a barrier opposing vascular permeability through 81 
a negatively charged molecular meshwork by limiting transvascular movement of molecules 82 
that are negatively charged, larger than 70-kDa, or both. By establishing a transvascular 83 
albumin gradient, it has been hypothesised that the intact glycocalyx regulates transvascular 84 
fluid flux following the so-called revised Starling equation or revised Starling principle[8]. The 85 
revised Starling principle states that transvascular exchange of fluid no longer occurs according 86 
to a simple gradient of hydrostatic and oncotic pressures across the capillary wall. Rather, the 87 
endothelial glycocalyx layer generates a virtually protein-free space between the glycocalyx 88 
and the endothelial cell membrane. Thereby, the oncotic gradient is moved from being between 89 
the plasma and the interstitium to being between the plasma and the protein-free space between 90 
glycocalyx and endothelial cell membrane. The ‘transglycocalyx’ oncotic pressure replaces the 91 
interstitial oncotic pressure as the key force opposing fluid filtration in the revised 92 
equation[12]. A further major change to the Starling principle is that, according to the revised 93 
principle, the oncotic pressure difference across the endothelial glycocalyx layer can oppose, 94 
but not reverse, the filtration rate[8]. This is referred to as the ‘no absorption’ rule and states 95 
that raising the oncotic pressure in the plasma cannot recruit fluid from the interstitial space. 96 
However, not only the glycocalyx but also the underlying endothelium influence permeability. 97 
The double-barrier concept stipulates that simultaneous disruption of the endothelial cell 98 
barrier and glycocalyx is needed to readily increase vascular permeability. While damage to 99 
5 
 
the glycocalyx alone overlying a tight cellular barrier has minimal effect on permeability, 100 
identical glycocalyx damage overlying a leaky cellular monolayer will rapidly increase fluid 101 
eflux[11]. The effects of glycocalyx damage therefore depend on the underlying endothelial 102 
cell phenotype and vary between and probably also within tissues[11]. When glycocalyx-103 
dependent permeability changes within the systemic vasculature are studied, it is therefore 104 
important to consider how both, glycocalyx structural adaptations and the underlying 105 
endothelial cell phenotype, will influence detectable permeability changes[11]. The new 106 
concept of the revised Starling principle has possible clinical implications: According to the no 107 
absorption rule, use of colloids to prevent or treat oedema would be fruitless as fluid cannot be 108 
reabsorbed[8]. The clinical applicability of this theory has been questioned as infusions of 109 
hyperosmolar and hyperoncotic solutions seem to increase the intravascular volume well 110 
beyond the infused volume suggesting that recruitment of interstitial fluid into the intravascular 111 
space takes place[10; 13]. Anecdotally, a poor correlation between albumin concentration and 112 
the presence or absence of peripheral oedema is occasionally noted in sick horses. The revised 113 
Starling principle offers an attractive explanation why even with very low albumin 114 
concentrations minimal oedema might be observed, providing the glycocalyx layer is intact, 115 
maintaining the protein-free space above the endothelium. On the other end of the spectrum, 116 
massive interstitial fluid accumulation might be observed with severe damage to this internal 117 
barrier, as seen in states of systemic inflammation, despite relatively normal albumin 118 
concentrations[14]. 119 
 120 
Glycocalyx and fluid therapy 121 
Intravenous fluid therapy is an important part of managing critically ill horses or horses 122 
undergoing general anaesthesia. Pathological injury to the glycocalyx occurs in ischaemia–123 
reperfusion, inflammation, sepsis, shock, hyperglycaemia, burns and excessive shear 124 
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stress[12]. There is increasing evidence that iatrogenic interventions such as fluid therapy 125 
influence the integrity of the glycocalyx and can even worsen the injury from the initial 126 
pathological events[15]. Rapid crystalloid or colloid fluid administration induce endothelial 127 
glycocalyx shedding in people and dogs[16; 17]. Proposed mechanisms include hemodilution 128 
of plasma components and potential osmotic changes.  129 
Elimination of infused fluid during surgery and anaesthesia decreases to approximately 130 
10%–20% of that in a conscious state due to the effects of the procedure and anaesthetics on 131 
adrenergic activity and levels of aldosterone, antidiuretic hormone, and renin. The half-life of 132 
crystalloids can be up to 10 times longer under general anaesthesia augmenting plasma volume 133 
expansion and increasing the risk of hypervolaemia and peripheral fluid accumulation[14]. The 134 
effect of hypervolaemia on the glycocalyx is controversial[18]. Hypervolaemia has been 135 
postulated to damage the glycocalyx, at least partially by triggering the release of atrial 136 
natriuretic peptide (ANP) that caused an increase in vascular permeability and histological 137 
degradation of the glycocalyx in an animal model[19]. Findings in human patients with induced 138 
hypervolaemia (15-25ml/kg/h) during routine surgery are conflicting with some finding 139 
evidence of ANP release and glycocalyx shedding[20; 21] while others did not[22]. However, 140 
almost all studies showed proportionate fluid retention following high volume infusions under 141 
general anaesthesia. Use of such high fluid rates would be rare in routine equine surgeries but 142 
clinicians should still be aware of the increased risk of fluid accumulation during general 143 
anaesthesia and possible associated risks of hypervolaemia.  144 
Hypernatraemia, induced by infusion of hypertonic saline, is equally controversial, 145 
damaging the glycocalyx in some experimental studies[23] but not in others[24]. Acute and 146 
chronic hyperglycaemia also compromises the glycocalyx[2] and high glucose concentrations 147 
(11.1mmol/L) may exacerbate sepsis-induced vascular endothelial activation and injury and 148 
glycocalyx degradation[25]. Choice of resuscitation fluid might also influence glycocalyx 149 
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damage and recovery. Haemorrhagic shock is associated with glycocalyx shedding and 150 
increased vascular permeability. Compared to crystalloids, using hydroxyethyl starch (HES) or 151 
plasma for resuscitation might improve vascular barrier function and glycocalyx recovery[26; 152 
27]. Different colloids might have different effects and not only the oncotic properties, but also 153 
the relative ability to protect and restore the endothelial glycocalyx could be relevant. Although 154 
HES increased colloid oncotic pressure more than albumin in a study using isolated guinea pig 155 
hearts, the reduction in capillary permeability was less compared to albumin. This was 156 
attributed to the ability of albumin to be partially incorporated into the glycocalyx layer[28]. 157 
In vitro and in vivo studies suggest that albumin and fresh frozen plasma might be superior to 158 
crystalloids and artificial colloids as resuscitation fluids, particularly during haemorrhagic 159 
shock, but prospective clinical studies are needed to confirm these findings[29]. Current 160 
recommendations for fluid therapy and resuscitation in people have not yet changed greatly in 161 
light of these findings but emphasise the importance of avoiding fluid overload, sever 162 
hypernatraemia and hyperglycaemia[12; 24]. It is probably prudent to heed this advice in in 163 
horses, too. 164 
 165 
Intravascular inflammation and coagulation 166 
The intact endothelium has multiple anticoagulant and profibrinolytic properties including the 167 
production and release of nitric oxide, prostacyclin and tissue factor pathway inhibitor[30]. 168 
Endothelial cells also secrete heparan sulfate, which augments the anticoagulant action of 169 
antithrombin through binding of antithrombin in plasma to heparan sulfate located on the 170 
luminal surface and in the basement membrane of the endothelium. Antithrombin’s 171 
anticoagulant activity is known to increase dramatically when bound to heparan sulfate on the 172 
endothelial glycocalyx[31]. During inflammatory conditions, such as sepsis and acute 173 
respiratory distress syndrome, glucuronidases, including heparanases, reactive oxygen species 174 
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and other proteases, disrupt the glycocalyx, exposing adhesion molecules for leucocytes and 175 
platelets such as E-selectin and intercellular adhesion molecule 1 on the denuded 176 
endothelium[2; 32]. Exposure of the adhesion molecules and a decrease in the antithrombotic 177 
properties leads to leucocyte and platelet recruitment, and fibrin and thrombus formation. 178 
While this is initially a beneficial process, aiming to trap and eliminate invading 179 
microorganisms, excessive activation can lead to altered blood flow, impaired oxygen delivery 180 
and subsequent organ failure[33-35]. Circulating syndecan-1 and hyaluronan concentrations 181 
have repeatedly been associated with disease severity, particularly in sepsis, and development 182 
of disseminated intravascular coagulation (DIC)[36-38]. The search for effective treatments 183 
for sepsis and DIC has been ongoing for decades and currently some hope is placed in therapies 184 
that either prevent or limit damage to the glycocalyx or accelerate its regeneration. As 185 
mentioned, judicious fluid therapy and use of plasma or albumin have been proposed but 186 
require further investigation. Inhalation anaesthesia using sevoflurane has been suggested to 187 
have glycocalyx-protecting or regenerating effects in some studies[39; 40] but this was not 188 
confirmed by others[22; 41]. Other drugs with possible benefits include corticosteroids, 189 
antithrombin, heparin and heparinoids[42]. Large scale clinical trials for these drugs in mainly 190 
septic patients, used with a different rational, so far failed to demonstrate beneficial results 191 
consistently[43]. New treatment approaches include glycocalyx components and enzyme 192 
inhibitors to prevent shedding, factors to accelerate angiogenesis and nanomaterial and 193 
glycocalyx-mimetic biomaterials. Results of clinical trials are still outstanding[44]. 194 
 195 
While the endothelial glycocalyx is unquestionable of great physiological and 196 
pathophysiological importance, research is still in its infancy. Until targeted treatments are 197 
fully investigated, avoiding iatrogenic damage by using judicious fluid therapy and avoiding 198 
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